Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Advances in Photodynamic Therapy"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 November 2015).
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
Tel. +1-617 726 6182; Fax: +1 617 726 6643
Interests: photodynamic therapy (PDT); low-level light therapy (LLLT); wound healing and infectious disease; atherosclerotic vulnerable plaque; anti-tumor immunity; photochemical mechanisms
Special Issues and Collections in MDPI journals
Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA
BAR 407, Wellman Center for Photomedicine, Massachusetts General Hospital, 40 Blossom Street, Boston, MA 02114, USA
Fax: +1 617-726-6643
Interests: photodynamic therapy; antimicrobial photoinactivation; photochemical mechanisms
This Special Issue “Advances in Photodynamic Therapy” will cover a selection of recent research topics and current review articles in the field of Photodynamic Therapy and Photodynamic Inactivation. Experimental papers, up-to-date review articles, and commentaries are all welcome.
The principle of photodynamic action was discovered over 110 years ago and its use as photodynamic therapy (PDT) for cancer, infections, and a range of other diseases has been studied for over 40 years. Nevertheless, it is fair to say that PDT has only been adopted as a mainstream treatment in a few specialties, such as dermatology and ophthalmology. The mechanism of action relies on absorption of harmless visible light by a non-toxic compound, called a photosensitizer that will go on to produce reactive oxygen species, such as singlet oxygen, which destroy cancer cells, blood vessels, and pathogenic microorganisms. Research advances include the design and testing of new photosensitizers, the targeting of photosensitizers by molecular recognition, the combination of nanotechnology and nanoparticles, the understanding of cell signaling pathways, antimicrobial photoinactivation, the influence of PDT on the host immune system, new light delivery methods and dosimetry techniques, new animal models, and well-controlled clinical trials for various diseases.
Prof. Dr. Michael R. Hamblin
Dr. Ying-ying Huang
- Photodynamic therapy
- antimicrobial photoinactivation
- drug delivery
- anti-tumor immunity
- clinical trials